SCN1A and Dravet syndrome: Based on this, using a second cohort of mice, we investigated whether Ant-134 dose (0.1 nmol) injected at P21 would reduce the frequency of spontaneous seizures and SUDEP (recorded by vEEG and video monitoring) experienced by F1.Scn1a(+/−)tm1kea mice until P28 during the worsening stage of DS (Fig. 2A, n = 6 mice per group).